Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer by 源�洹� et al.
406https://e-kcj.org
ABSTRACT
Background and Objectives: There are limited data on the use of non-vitamin K antagonist 
oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with cancer. We aimed to 
assess the efficacy and safety of NOACs in AF patients with cancer in this study.
Methods: In 2,568 consecutive non-valvular AF patients with newly diagnosed cancer, we 
analyzed ischemic stroke/systemic embolism (SE), major bleeding, and all-cause death. 
Based on propensity score matching, 388 matched pairs were included in the NOAC and 
warfarin groups.
Results: Patient baseline characteristics were comparable between the matched groups. 
During median follow-up of 1.8 years, the NOAC group had significantly lower incidences of 
ischemic stroke/SE (p<0.001), major bleeding (p<0.001), and all-cause death (p<0.001) than 
the warfarin group. Moreover, the incidence of major bleeding was significantly lower in the 
NOAC group than in the warfarin group with optimal international normalized ratio control 
(p=0.03). Especially, within 1 year after cancer diagnosis, the incidences of all clinical events 
were significantly lower in the NOAC group than in the warfarin group.
Conclusions: In AF patients with newly diagnosed cancer, NOACs showed lower incidences 
of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 
year after cancer diagnosis.
Keywords: Atrial fibrillation; Hemorrhage; Neoplasms; Stroke; Anticoagulants
INTRODUCTION
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% 
of the general population.1) AF is associated with a 5-fold increase in the stroke risk, and 1 in 
5 cases of stroke is attributed to this arrhythmia.2) Multiple clinical trials have demonstrated 
the superior therapeutic effect of warfarin compared to that of placebo in the prevention of 
thromboembolic events among patients with non-valvular AF.3) However, AF patients with 
comorbidities have a concomitant risk of fatal bleeding, and therefore, clinicians might be 
reluctant to use vitamin K antagonists (VKAs) despite a high stroke risk.4)5) AF is common 
in patients with life-threatening cancer and those undergoing active cancer treatments.6) 
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Several studies have suggested that the association between cancer and AF is not limited 
to the postoperative period.7)8) Despite the excellent effects of VKAs in the prevention of 
thromboembolisms, VKAs might result in an elevated bleeding risk in patients with cancer 
and a history of non-valvular AF because of poor international normalized ratio (INR) 
control.5)9) Moreover, it is difficult to achieve therapeutic drug levels in cancer patients owing 
to the risk of drug interactions, malnutrition, and vomiting in these patients.5)
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new additional option for 
stroke prevention in AF patients, which are considered at least as effective and safe as VKAs.10) 
NOACs have a wide therapeutic window, low inter- and intra-individual variability, and no 
clear interactions with food, and there is no need for frequent laboratory monitoring and dose 
adjustments.10-12) However, there are little controlled data on the use of NOACs in AF patients 
with cancer, and active cancer was usually an exclusion criterion in randomized NOAC trials.13) 
We hypothesized that NOAC administration would result in favorable clinical outcomes in 
AF patients with newly diagnosed cancer. The aim of this study was to evaluate the safety and 
efficacy of NOACs in AF patients with cancer by comparing the findings with those for patients 
receiving NOACs and warfarin. Additionally, we evaluated the clinical outcomes according to 
time of cancer diagnosis, and dosage and types of NOACs in this study.
METHODS
Patients
The study protocol was approved by the Institutional Review Board of Severance 
Cardiovascular Hospital, Seoul, Korea (4-2016-0105) and complied with the Declaration 
of Helsinki. No informed consent was required for study populations. Between November 
2005 and June 2015, we identified 2,568 consecutive patients with non-valvular AF who were 
newly diagnosed with cancer in Yonsei University Severance Hospital. The study subjects 
were followed up until they developed an event or until the last follow-up date whichever 
came first. Patients who were not prescribed any oral anticoagulants (OACs; n=867), those 
who underwent radiofrequency catheter ablation or cardioversion (n=5), and those who had 
insufficient clinical data (n=45) were excluded. Finally, we enrolled 1,651 patients in this 
study. The patients were divided into the following 2 groups according to treatment: NOAC 
group (n=572) and warfarin group (n=1,079; Figure 1).
AF was documented using 12-lead electrocardiography or 24-hour Holter recordings. The 
patients' medical records were reviewed. The patient databases were searched to identify 
any known or putative risk factors for ischemic stroke.14) Heart failure was considered 
when hospitalized patients had appropriate symptoms (shortness of breath, fatigue, fluid 
retention, or any combination of these symptoms) and clinical signs of fluid retention 
(pulmonary or peripheral) with explainable abnormalities of the cardiac structure and 
function.15) The congestive heart failure, hypertension, age ≥75 years (doubled), diabetes 
mellitus, previous stroke or transient ischemic attack (doubled), vascular disease, age 
65–74 years, and gender category (female) (CHA2DS2-VASc) and hypertension, abnormal 
renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (age >65 
years), drugs/alcohol concomitantly (HAS-BLED) scores were evaluated. Bleeding history 
was defined as follows: Intracranial, hospitalization, hemoglobin decrease >2 g/L, and/
or transfusion. Drugs/alcohol concomitantly was defined as concurrent use of antiplatelet 
agents (include aspirin, clopidogrel, cilostazol, prasugrel, or ticagrelor), nonsteroidal 
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anti-inflammatory drugs; one point for drugs plus one point for alcohol excess, maximum 
2 points.16) Renal insufficiency was considered when serum creatinine was >2 mg/dL, and 
abnormal liver function was considered when cirrhosis, bilirubin >2 times the upper limit 
of normal (ULN), or aspartate aminotransferase/alanine transaminase/alkaline phosphatase 
>3 times the ULN was noted. Dialysis patients and cirrhosis patients were excluded owing 
to the indication of NOAC. Mean INR values and time in therapeutic range (TTR) of INR 
2.0–3.0 were calculated using the linear interpolation methods proposed by Rosendaal et 
al.17) The percentage of time during which a patient had an INR within 2.0 to 3.0 was taken as 
the TTR. According to the center's protocol, INR was measured every 8–12 weeks and more 
frequently when it was not within the therapeutic range. The full doses of NOAC were defined 
as 150 mg twice for dabigatran, 5 mg twice for apixaban, and 20 mg once for rivaroxaban. 
The indication of the reduced dose followed the current guideline (dabigatran 110 mg twice 
a day if patients are aged ≥80 or have an estimated glomerular filtration rate [eGFR] of 30–50 
mL/min; rivaroxaban 15 mg once a day if eGFR is 15–49 mL/min; apixaban 2.5 mg twice a day 
if 2 of the 3 following criteria are present: age ≥80 or serum creatinine ≥1.5 mg/dL or body 
weight ≤60 kg).10) eGFR was calculated by Cockroft-gault equation.18) Doses not listed above 
(apixaban 2.5 mg once or rivaroxaban 10 mg once, etc.) were excluded as off-label dose.
Follow-up
The follow-up period was defined as the period from the date of cancer diagnosis to the date 
of an event or the date of the last visit if an event did not occur. We also set the study endpoint 
as the point when the first anticoagulation strategy was stopped or changed, according to on-
treatment analysis. We evaluated ischemic stroke/systemic embolism (SE), major bleeding, 
and all-cause death during the follow-up. Ischemic stroke was defined as a neurological 
deficit with a sudden onset that persisted for >24 hours corresponding to a vascular territory 
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Patients with a history of non-valvular AF
who has been diagnosed newly developed cancer
during 1 November, 2005 through 30 June, 2016
(n=2,568)
NOAC
(n=572)
Warfarin
(n=1,079)
 1:1 propensity score matching (n=776)
Excluded (n=917)
      -Did not use oral anticoagulants (n=867)
      -Insufficient clinical data (n=32)
      -Who underwent RFCA or cardioversion (n=5)
      -End-stage renal disease (n=5)
      -Liver cirrhosis (n=4)
      -Off-label NOAC dose (n=4)
NOAC
(n=388)
Warfarin
(n=388)
Figure 1. Flowchart of patients participating in this study. 
AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; RFCA = radiofrequency catheter ablation.
in the absence of primary hemorrhage and was not explained by other causes, including 
trauma, infection, and vasculitis.19) Major bleeding was defined according to the definition 
by the International Society on Thrombosis and Haemostasis.20) When a patient experienced 
both ischemic stroke/SE and major bleeding during the follow-up period, each event was 
counted separately. However, when analyzing the Kaplan-Meier cumulative incidence rate, we 
considered the first event only.
Statistical analysis
Normally distributed continuous variables are presented as mean±standard deviation, 
and compared using Student's t-test for parametric data and the Mann-Whitney U test 
for nonparametric data. Categorical variables are presented as number (percentage), and 
compared using the χ2 test or Fisher's exact test.
To reduce the effect of selection bias and potential confounding cohort study, estimated 
propensity scores (PSs) were used to match the patients who received NOACs to patients who 
received warfarin. PSs were estimated using a non-parsimonious multiple logistic regression 
model for the NOAC and warfarin groups. The following variables were considered: age, 
sex, hypertension, diabetes mellitus, heart failure, chronic kidney disease, history of stroke 
or transient ischemic attack, history of myocardial infarction or peripheral vascular disease, 
history of hemorrhage, concomitant antiplatelet, type of cancer, rate of metastatic cancer, 
and follow-up duration. Cases were then matched, without replacement, with controls 1:1 
based on the closest possible value of the PS (nearest neighbor matching). We evaluated 
the balance between treatment populations according to standardized differences of all 
baseline covariates, using a threshold of 0.1 to indicate imbalance.21) A matching caliper of 
0.2 standard deviations of the logit of the estimated PS was enforced to ensure that matches 
of poor fit were excluded. The matching procedure was performed using R packages (R 
Foundation, Vienna, Austria). Based on PS matching, 388 matched pairs were included in the 
NOAC and warfarin groups. Kaplan-Meier curves for cumulative incidence rate were plotted 
for the NOAC and warfarin groups and were compared using the log-rank test. All statistical 
analyses were performed using R version 3.1.1 (http://www.r-project.org/). A p value <0.05 
was considered statistically significant.
RESULTS
Patient characteristics
The overall clinical characteristics of the patients are presented in Table 1. The patient age 
was greater in the NOAC group than in the warfarin group (74.2±8.3 vs. 67.5±8.0 years, 
p<0.001). The prevalence of hypertension, diabetes, congestive heart failure, stroke/
transient ischemic attacks, and major bleeding was higher in the NOAC group than in the 
warfarin group (all p<0.001). Additionally, the CHA2DS2-VASc and HAS-BLED scores were 
higher in the NOAC group than in the warfarin group (CHA2DS2-VASc: 3.8±1.7 vs. 3.4±1.4, 
p<0.001; HAS-BLED: 2.0±1.0 vs. 1.8±1.2, p<0.001). Stomach cancer was the most common 
malignancy, followed by colorectal cancer (Supplementary Table 1). There was no patient 
who was prescribed concomitant dual antiplatelet agents with OACs. After PS matching, 
the baseline characteristics were well matched between the NOAC and warfarin groups. 
The median follow-up duration was comparable between the NOAC and warfarin groups 
(1.8 vs. 1.7 years, p=0.593). Baseline characteristics of patient without OAC was shown in 
Supplementary Table 2.
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Comparison between the NOAC and warfarin groups
During the median follow-up period of 1.8 years, the cumulative incidence rates of ischemic 
stroke/SE, major bleeding, and all-cause death were lower in the NOAC group than in the 
PS-matched warfarin group (Figure 2). The rates of ischemic stroke/SE, major bleeding, and 
all-cause death in the matched population are presented in Table 2. The rates of ischemic 
stroke/SE (1.3% vs. 5.9%/year, p<0.001), major bleeding (1.2% vs. 5.1%/year, p<0.001), and 
all-cause death (6.1% vs. 13.3%/year, p<0.001) were lower in the NOAC group than in the 
PS-matched warfarin group. With regard to ischemic stroke, the incidence rate was 1.3%/
year in the NOAC group and 5.5%/year in the warfarin group (p<0.001). With regard to major 
bleeding, the gastrointestinal bleeding rate was 1.0%/year in the NOAC group and 3.5%/year 
in the warfarin group (p=0.001). Additionally, the intracranial bleeding rate was 0.2%/year in 
the NOAC group and 1.1%/year in the warfarin group (p=0.02).
Time after cancer diagnosis and anticoagulation
The numbers of patients with ischemic stroke/SE, major bleeding, and all-cause death 
according to the duration after cancer diagnosis are presented in Figure 2. Within 1 year after 
cancer diagnosis, there were 7 ischemic stroke/SE events (1.9%/year) in the NOAC group 
and 26 events (7.9%/year) in the warfarin group (Figure 3; p<0.001). Between 1 and 2 years 
after cancer diagnosis, there was 1 stroke event (0.3%/year) in the NOAC group and 8 events 
(2.5%/year) in the warfarin group (p=0.01; Figure 3). There were similar trends in major 
bleeding (1.1 vs. 7.9%/year within 1 year; p<0.001 and 0.8 vs. 1.9%/year between 1 and 2 years; 
p=0.25) and all-cause death (7.2 vs. 17.2%/year within 1 year; p<0.001 and 3.2 vs. 7.0%/year 
between 1 and 2 years; p=0.03).
Clinical outcomes according to different anticoagulation strategies
Figure 4 presented clinical outcomes according to different anticoagulation strategies. A TTR 
≥60% was achieved in 61 of 328 patients in the warfarin group (18.6%). The NOAC group 
showed significantly lower rates of ischemic stroke/SE, major bleeding, and all-cause death 
than the TTR <60% group (all p<0.01). However, compared with the TTR ≥60% group, the 
NOAC group showed similar ischemic stroke/SE, but significantly lower major bleeding rates 
(p=0.03; Supplementary Figure 1).
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Table 1. Baseline characteristics of the PS-matched patients
Characteristic Overall PS-matched
NOAC (n=572) Warfarin (n=1,079) SMD (%) p value* NOAC (n=388) Warfarin (n=388) SMD (%) p value*
Age (years) 74.2±8.3 67.5±8.0 74.9 <0.001 72.4±7.0 72.4±6.2 0.7 0.10
Female 180 (31.5) 387 (35.9) 9.4 0.08 121 (31.2) 123 (31.7) 1.1 0.94
Prior stroke or transient ischemic attack 175 (30.6) 288 (26.7) 8.9 0.09 120 (30.9) 120 (30.9) <0.1 0.82
Prior vascular disease (MI or PAD) 33 (5.8) 9 (0.8) 27.8 <0.001 10 (2.6) 8 (2.1) 3.4 >0.999
Prior major bleeding 86 (15.0) 114 (10.6) 13.3 0.01 67 (15.7) 47 (12.1) 10.0 0.18
Hypertension 485 (84.8) 804 (74.5) 25.8 <0.001 319 (82.2) 316 (81.4) 2.0 0.85
Diabetes mellitus 233 (40.7) 403 (37.3) 7.1 0.18 155 (39.9) 149 (38.4) 3.2 0.71
Congestive heart failure 107 (18.7) 295 (27.3) 78.3 <0.001 70 (18.0) 70 (18.0) <0.1 >0.999
Concurrent antiplatelet 83 (14.5) 179 (16.6) 5.8 0.52 35 (9.0) 35 (9.0) <0.1 >0.999
Chronic kidney disease 35 (6.1) 127 (11.8) 19.9 0.01 35 (9.0) 35 (9.0) <0.1 >0.999
Metastatic cancer 73 (12.7) 153 (14.2) 4.2 0.46 53 (13.7) 45 (11.6) 6.2 0.45
CHA2DS2-VASc score 3.8±1.7 3.4±1.4 20.9 <0.001 3.6±1.6 3.6±1.5 0.3 0.89
HAS-BLED score 2.0±1.0 1.8±1.2 74.4 <0.001 2.0±1.0 2.0±1.1 0.5 0.52
Data are presented as mean±standard deviation or number (percentage).
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, previous stroke or transient ischemic attack (doubled), 
vascular disease, age 65–74 years, and gender category (female); HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile INR, elderly (age >65 years), drugs/alcohol concomitantly; MI = myocardial infarction; NOAC = non-vitamin K antagonist oral anticoagulant; 
PAD = peripheral artery disease; PS = propensity score; SMD = standardized mean difference.
*All p values were not statistically significant.
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Table 2. Clinical outcomes according to anticoagulation strategies (PS-matched populations)
Event
NOAC  
(n=388)
Warfarin 
(n=388) p value
Full NOAC 
(n=109)
Reduced 
NOAC (n=279) p value
Dabigatran 
(n=140)
Apixaban 
(n=138)
Rivaroxaban 
(n=110) p value
Number Rate Number Rate Number Rate Number Rate Number Rate Number Rate Number Rate
Ischemic stroke/SE 9 1.3 40 5.9 <0.001 2 0.9 7 1.4 0.98 2 0.7 4 1.8 3 1.6 0.53
Ischemic stroke 9 1.3 39 5.5 <0.001 2 0.9 7 1.4 0.63 2 0.7 4 1.8 3 1.6 0.53
SE 0 0 1 0.4 0.27 0 0 0 0 NA 0 0 0 0 0 0 NA
Major bleeding 8 1.2 36 5.1 <0.001 2 0.9 6 1.2 0.74 3 1.0 3 1.3 2 1.0 0.93
Intracranial 1 0.2 8 1.1 0.02 0 0 1 0.2 0.51 0 0 1 0.4 0 0 0.33
Gastrointestinal 7 1.0 25 3.5 0.001 2 0.9 5 1.0 0.90 3 1.0 2 0.9 2 1.0 >0.999
Other sites 0 0 4 0.6 0.20 0 0 0 0 NA 0 0 0 0 0 0 NA
All-cause death 41 6.1 93 13.3 <0.001 10 4.8 31 6.6 0.45 13 4.4 14 6.7 14 8.1 0.28
Event rate was described as event per 100-patient years.
NA = not applicable; NOAC = non-vitamin K antagonist oral anticoagulant; PS = propensity score; SE = systemic embolism.
No. at risk
NOAC 388 378 303 264 131
Warfarin 388 344 292 240 209
No. at risk
NOAC 388 375 299 258 124
Warfarin 388 333 271 218 183
No. at risk
NOAC 388 379 306 267 133
Warfarin 388 346 293 246 212
 C
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Figure 2. Cumulative incidence of ischemic stroke/SE, major bleeding, and all-cause death in the PS matched NOAC and warfarin groups. 
NOAC = non-vitamin K antagonist oral anticoagulant; PS = propensity score; SE = systemic embolism.
In the NOAC group, dabigatran, apixaban, and rivaroxaban were prescribed in 140 (36.1%), 
138 (35.6%), and 110 (28.3%) patients, respectively. Full NOAC dose was prescribed in 109 
(28.1%) patients. Among 279 (71.9%) patients with reduced NOAC dose, 129 patients were 
prescribed reduced dose according to indication and 150 patients were underdosed. The rates 
of ischemic stroke/SE, major bleeding, and all-cause death were not significantly different 
between the full and reduced NOAC dose groups. Likewise, there were no significant 
differences according to the NOAC type (Table 2). In subgroup analysis according to cancer 
type and stage, p values for interaction were not significant (Supplementary Figure 2).
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Figure 3. Proportion of patients with events according to the duration after cancer diagnosis in the PS matched NOAC and warfarin groups. 
NOAC = non-vitamin K antagonist oral anticoagulant; PS = propensity score; SE = systemic embolism.
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Figure 4. Cumulative incidence rates of all clinical events according to anticoagulation strategy. (A) Ischemic stroke/SE, (B) major bleeding, (C) all-cause death. 
NOAC = non-vitamin K antagonist oral anticoagulant; SE = systemic embolism; TTR = target therapeutic range. 
*Warfarin and TTR <60% groups showed significantly higher rates of all clinical events than NOAC group, †TTR ≥60% group showed significantly higher rates of 
major bleeding than NOAC group.
DISCUSSION
All clinical outcomes, including ischemic stroke/SE, major bleeding, and all-cause death, 
were better in the NOAC group than in the PS-matched warfarin group. Additionally, the 
rate of major bleeding was significantly lower in the NOAC group than in the optimal INR 
control (TTR ≥60%) group. Especially, within 1 year after cancer diagnosis, the incidences of 
all clinical outcomes were significantly lower in the NOAC group than in the warfarin group. 
Finally, there was no significant difference in the clinical outcomes according to NOAC 
dosage and type. These findings suggest that NOACs could be considered for anticoagulation 
in AF patients with newly diagnosed cancer.
Large studies have suggested that the occurrence of thromboembolisms is 4- to 8-fold higher 
in patients with active cancer than in those without cancer.22) However, warfarin is largely 
underused because of concerns regarding the need for systematic monitoring and the risk of 
bleeding complications.23) Previous studies have shown that it is difficult to obtain an optimal 
range of the INR in cancer patients owing to cancer treatment.5) It is difficult to maintain a 
stable INR in the setting of the concomitant use of chemotherapy agents. Furthermore, cancer 
itself and other invasive procedures may induce fatal bleeding.10)24) In our study, it is notable that 
867 patients were not treated with oral anticoagulation and were therefore excluded from the 
study. The exact reason for not receiving anticoagulation was not known. Maybe a relatively high 
proportion of metastatic cancers is associated with short life expectancies and higher bleeding 
tendency, and therefore it is possible that anticoagulants were not prescribed. Other unspecified 
factors, such as patient preferences, might have been taken into account for not prescription of 
OACs. In concerns of major bleeding complication, warfarin was often underdosed and NOAC 
was prescribed at a reduced dose. In our study, NOACs showed significantly lower incidence 
rates of all clinical outcomes than warfarin, and lower major bleeding rate when compared with 
optimally controlled warfarin group. This suggests that the worse outcomes of warfarin are 
related to poor achievement of optimal TTR and that NOAC may be more useful in this situation.
Cancer patients were excluded in previous randomized clinical studies, and there were few 
cancer patients in phase 3 AF trials.13)25-27) Subgroup analysis suggested that the net benefit 
of NOACs appears to be better than that of warfarin in situations in which the quality of oral 
anticoagulation is poor.28) Our previous study found that 10% of warfarin-treated cancer patients 
achieved ≥60% of the TTR during follow-up. The composite endpoint was better in patients 
with TTR ≥60% than in those with TTR <60% and without oral anticoagulation therapy.5) In 
present study, the TTR ≥60% group showed lower rates of ischemic stroke/SE and all-cause 
death when compared to the rates in the TTR <60% group, whereas major bleeding events were 
not statistically significant according to TTR. Patients in the TTR <60% group were mostly 
prescribed underdosed warfarin, and this resulted in a lower incidence of major bleeding.
Interestingly, although 71.9% of patients in NOAC group received reduced doses of NOACs, 
clinical outcomes were not significantly different between the reduced dose and full dose groups. 
In terms of major bleeding, the frequency of a reduced dose was somewhat higher, although not 
statistically significant. This may be associated with a stronger bleeding tendency that could not 
be noted in the reduced dose group. In general, Asians have a smaller body size and body mass 
index than non-Asians who have been used as subjects in many previous large-scale randomized 
studies.13)26)27) In the J-ROCKET AF trial, it was found that 15 mg of rivaroxaban in Japanese 
patients was equivalent to 20 mg of rivaroxaban in Caucasians with regard to the pharmacokinetic 
profile.29) Furthermore, Chan et al.30) reported that low doses of rivaroxaban and dabigatran 
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reduced the risk of ischemic stroke and bleeding in Taiwanese people when compared to the 
effect with warfarin. Our study also suggested that low doses of NOACs have superior efficacy 
when compared to that of warfarin, which may be used more safely in cancer patients.
Approximately 7 of 10 patients with all clinical events showed the events within 1 year after 
cancer diagnosis. In the early stage of cancer treatment, it is very difficult to maintain proper 
medication dose due to invasive anticancer treatment such as surgery or biopsy. Therefore, 
clinical outcomes are likely to occur during early cancer diagnosis. In the present study, 
NOACs showed lower incidences of all clinical outcomes within 1 year after cancer diagnosis 
than warfarin. NOACs are known to have a short onset time, short half-life, and low drug to 
drug interactions compared to warfarin, and this characteristic may be helpful in the early 
diagnosis of cancer in which anticoagulation is frequently interrupted.12) Therefore, NOACs 
could be considered in AF patients with newly diagnosed cancer, especially within 1 year after 
cancer diagnosis.
The present study has several limitations. First, this was a retrospective and non-randomized 
study, and therefore, it had all the limitations of such studies. To reduce the effect of selection 
bias and possible confounding in this retrospective cohort study, estimated PSs were 
used, and most of the baseline characteristics, including the follow-up duration, were well 
matched. The second limitation is difference in time of enrollment between study groups. 
Starting in 2015, the number of patients in NOAC group was greater than warfarin, and 
patients in the warfarin group were enrolled earlier than NOAC group. This difference was 
corrected by PS matching and limiting maximum follow-up duration, but this difference is 
a critical limitation of this study. The third limitation is a relatively small number of study 
populations. Because of this, the effectiveness of the reduced dose in cancer patients and 
the differences in the type of NOAC could not be clarified. Further large-scale and long-term 
follow-up studies would be needed to clarify these questions. Fourth, the heterogenicity of 
cancer might resulted in bias. However, the distribution of cancer was well matched in PS-
matched population. Fifth, the chemotherapy drug, and the information of surgery were not 
investigated. Especially, types of chemotherapy drugs and their durations were heterogenous 
and we were not able to get all the data. Considering that anticoagulation during 
chemotherapy may affect bleeding risk, the lack of this data is an important limitation of this 
study. Large-scale studies with a better design will be needed because the risks of bleeding 
and thrombosis different according to type of cancer, anticancer medication, and stage.
In AF patients with newly diagnosed cancer, all clinical events were less common with 
NOACs than with warfarin. Major bleeding rate was lower in NOAC group than optimal INR 
controlled warfarin group. Finally, although warfarin did not improve the clinical outcomes 
because of poor INR control caused by cancer treatment during the first year after the cancer 
diagnosis, NOAC was effective within 1 year. However, there were quite limitations and 
further well-controlled large-scale studies would be needed to clarify our results.
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Cumulative incidence rates of all clinical events between NOAC and well controlled warfarin 
(TTR ≥60%).
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Forest plot of subgroup analysis.
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